Diag2Tec is a preclinical CRO devoted to Hematological Malignancies.
We provide preclinical services including in vitro Drug Testing in Multiple Myeloma, Lymphoma, Leukemia derived Cell lines and Primary Cells from patients.
With our unique cellular models, genomic data, and our expertise, our mission is to provide efficient treatment solutions for patients suffering from Hematological Malignancies with Precision Medicine approaches. We support biotech and pharmaceutical companies to focus their preclinical drug development on the right molecules in the right indications.